NCT01381705View on ClinicalTrials.gov

Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma

CompletedOBSERVATIONAL
Enrollment

259

Participants

Timeline

Start Date

February 6, 2012

Primary Completion Date

July 6, 2012

Study Completion Date

July 6, 2012

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

GENETIC

DNA analysis

GENETIC

gene expression analysis

GENETIC

polymorphism analysis

OTHER

laboratory biomarker analysis

OTHER

medical chart review

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

ECOG-ACRIN Cancer Research Group

NETWORK

NCT01381705 - Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma | Biotech Hunter | Biotech Hunter